Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
11 lessons
9mRetatrutide is Lilly's investigational GIP, GLP-1 and glucagon receptor agonist. Understand the trial findings, how it differs from approved medicines, and why it is not available by prescription.
9mPhase 3 data on retatrutide side effects, in plain English: how often nausea, diarrhea, dysesthesia (skin burning), low blood pressure and injection-site reactions showed up by dose, and what the trials don't tell you.
7mPositive TRIUMPH-2 and TRIUMPH-3 results did not produce a 2026 filing. Lilly says the remaining work is in the CMC and manufacturing package.
Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
9mThe TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
7m31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mNew Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
9mEveryone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.
9mPhase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
12mRetatrutide is Lilly's investigational GIP/GLP-1/glucagon triple agonist. This hub covers what it is, what the trials actually reported about dosing and weight loss, how vial math works, where approval stands, and links to every retatrutide guide on PeptIQ.io.
Also available at /blog for legacy links.